Showing 7521-7530 of 8172 results for "".
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Victoria Kennedy receives ASLMS' First Leadership, Mentorship & Public Advocacy for Women in Medical Science Awardhttps://practicaldermatology.com/news/victoria-kennedy-receives-aslms-first-leadership-mentorship-public-advocacy-for-women-in-medical-science-award/2458628/Victoria Reggie Kennedy will receive the first Leadership, Mentorship & Public Advocacy for Women in Medical Science Award at the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS). The award will be presented at th
- FDA Clears Venus Versa for 20-Plus Common Clinical Indicationshttps://practicaldermatology.com/news/fda-clears-venus-versatm-for-20-plus-common-clinical-indications/2458632/The U.S. Food and Drug Administration cleared Venus Concept’s Venus Versa™ system for skin rejuvenation, hair removal, facial wrinkles and rhytides, skin resurfacing, pigmented and vascular lesions, and acne vulgaris.
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us
- Many Parents are Concerned About Fake Online MD Reviewshttps://practicaldermatology.com/news/many-parents-are-concerned-about-fake-online-md-reviews/2458637/More than two-thirds of parents believe some online doctor reviews are fake, while slightly fewer say there are not enough ratings to make a good decision, according a report from C.S. Mott Children’s Hospital National Poll on Children’s Health. More than half of p
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- Lumenis Supports the Launch of Restoring Heroes Foundation for Scar Patientshttps://practicaldermatology.com/news/lumenis-launches-restoring-heroes-foundation-for-scar-patients/2458658/Kim Phuc, the young girl who was immortalized in a photograph taken during the 1972 Napalm bombing, has come a long way since that fateful day. When the photo was taken, she was running away from her village, naked, after her clothing had been burnt off. South Vietnamese plane
- Galderma Laboratories Launches qilib Hair Care Linehttps://practicaldermatology.com/news/galderma-laboratories-launches-qilib-hair-care-line/2458659/Galderma Laboratories, L.P., launched qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement. The qilib portfolio features a dual action system to address hair thinning and hair loss. Despite the 80 million men and women in the US who suff
- Envy Medical Launches SilkPeel Daily Dermal Optimizerhttps://practicaldermatology.com/news/envy-medical-launches-silkpeel-daily-dermal-optimizer/2458663/Envy Medical, Inc., is launching its SilkPeel® Daily Der al Optimizer at the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, DC. Building off of the professional SilkPeel Diamo
- Valeant Pharmaceuticals Comments On Management Changehttps://practicaldermatology.com/news/valeant-pharmaceuticals-comments-on-management-change/2458668/Valeant Pharmaceuticals International, Inc. today issued the following comments in response to inquiries from investors regarding Deb Jorn's departure from Valeant.